Aduro BioTech Inc (NASDAQ:ADRO) – Research analysts at Oppenheimer issued their FY2022 EPS estimates for shares of Aduro BioTech in a research report issued to clients and investors on Friday, according to Zacks Investment Research. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will earn $0.10 per share for the year. Oppenheimer has a “Outperform” rating and a $13.00 price target on the stock.
A number of other equities research analysts have also commented on the company. Zacks Investment Research lowered Aduro BioTech from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. BidaskClub upgraded Aduro BioTech from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. Cantor Fitzgerald reiterated a “buy” rating and issued a $15.00 price target on shares of Aduro BioTech in a research report on Monday, March 5th. Bank of America cut their target price on Aduro BioTech from $9.00 to $8.00 and set an “underperform” rating on the stock in a research report on Friday, March 2nd. Finally, Canaccord Genuity restated a “buy” rating on shares of Aduro BioTech in a research report on Friday, March 2nd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. Aduro BioTech presently has an average rating of “Hold” and an average price target of $14.50.
Aduro BioTech (NASDAQ ADRO) traded up $0.45 during midday trading on Monday, hitting $9.25. The company’s stock had a trading volume of 874,469 shares, compared to its average volume of 571,389. Aduro BioTech has a 1 year low of $5.82 and a 1 year high of $14.05. The company has a market cap of $713.13 and a price-to-earnings ratio of -7.63.
In related news, COO Gregory W. Schafer sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $7.61, for a total transaction of $152,200.00. Following the transaction, the chief operating officer now directly owns 190,745 shares of the company’s stock, valued at approximately $1,451,569.45. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Dirk G. Brockstedt sold 65,223 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $8.11, for a total value of $528,958.53. Following the transaction, the executive vice president now directly owns 137,826 shares in the company, valued at $1,117,768.86. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,981 shares of company stock worth $1,423,682. 6.60% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the stock. MetLife Investment Advisors LLC acquired a new position in Aduro BioTech during the 4th quarter worth approximately $140,000. Vident Investment Advisory LLC raised its stake in Aduro BioTech by 40.4% during the 4th quarter. Vident Investment Advisory LLC now owns 154,140 shares of the biotechnology company’s stock worth $1,156,000 after buying an additional 44,325 shares during the period. Millennium Management LLC raised its stake in Aduro BioTech by 3.8% during the 4th quarter. Millennium Management LLC now owns 298,441 shares of the biotechnology company’s stock worth $2,238,000 after buying an additional 10,991 shares during the period. TIAA CREF Investment Management LLC raised its stake in Aduro BioTech by 17.9% during the 4th quarter. TIAA CREF Investment Management LLC now owns 126,577 shares of the biotechnology company’s stock worth $949,000 after buying an additional 19,236 shares during the period. Finally, Teachers Advisors LLC raised its stake in Aduro BioTech by 22.8% during the 4th quarter. Teachers Advisors LLC now owns 93,042 shares of the biotechnology company’s stock worth $698,000 after buying an additional 17,296 shares during the period. 44.94% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/03/14/aduro-biotech-inc-adro-expected-to-post-fy2022-earnings-of-0-10-per-share.html.
Aduro BioTech Company Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.